The first, single treatment for metabolically resistant bacteria.
A breakthrough method that activates resistant bacteria allowing for attack by both immune and drug regimens.
a problem todayAntibiotics have never been capable of targeting chronic infections.
a problem TOMORROWNumber of lives lost worldwide due to infections resistant to medications to treat them could increase to
70% by 2050
Most chronic infections are biofilm associated and metabolically resistant to current antibiotics.
Infections such as chronic sinusitis, chronic non healing wounds, COPD, cystic fibrosis, and many, many more remain untreatable today.
NIH & CDC estimate ~80% of chronic bacterial infections are biofilm-associated.
by
A solution that bridges the gaps by utilizing a novel mechanism that sensitizes and eliminates biofilm-associated bacteria.
By defanging pathogens as a novel mechanism, RelAQui inhibits RelA, a universal metabolic switch in bacteria used to overcome oxidative stress.
A CUT ABOVE THE RESTRelAQui’s novel mode of action allows for effective treatment by metabolically activating resistant bacterial cells allowing for attack by both immune and drug regimens.
MOA does not induce antibiotic resistance.
RelAQui allows for flexibility in treatment for use in both chronic and acute infections.
RelAQui treatment reduces time and cost for therapy, allowing patients to get better, faster.
Contact Us
Learn more about our breakthrough solutions by filling out the form below. Our team will respond as quickly as possible to your inquiry!